Tris Pharma and KYE Pharmaceuticals Inc. have entered into an agreement granting KYE exclusive rights to commercialize Tris’ FDA-approved ADHD product portfolio in Canada.  Under the agreement, KYE will also handle all ongoing Canadian regulatory activities for the products. “Partnering with Tris to bring this unique ADHD product portfolio to Canada is a defining opportunity,” said Doug Reynolds, President of KYE. “Tris’ products have the potential to address a ...